We previously reported that transplantation (Tx) of prevascularized donor islets as composite isletkidneys (IK) reversed diabetic hyperglycemia in both miniature swine and baboons. In order to enhance this strategy's potential clinical applicability, we have now combined this approach with hematopoietic stem cell (HSC) Tx in an attempt to induce tolerance in nonhuman primates. IKs were prepared by isolating islets from 70% partial pancreatectomies and injecting them beneath the autologous renal capsule of five rhesus monkey donors at least 3 months before allogeneic IK Tx. HSC Tx was performed after mobilization and leukapheresis of the donors and conditioning of the recipients with total body irradiation, T cell depletion, and cyclosporine. One IK was harvested for histologic analysis and four were transplanted into diabetic recipients. IK Tx was performed either 20-22 (n = 3) or 208 (n = 1) days after HSC Tx. All animals accepted IKs without rejection. All recipients required >20 U/day insulin before IK Tx to maintain <200 mg/dL, whereas after IK Tx, three animals required minimal doses of insulin (1-3 U/day) and one animal was insulin free. These results constitute a proof-of-principle that this IK tolerance strategy may provide a cure for both endstage renal disease and diabetes without the need for immunosuppression.
Introduction
Many persons with diabetes who have end-stage renal disease (ESRD) are placed on hemodialysis to compensate for their decline in renal function. However, almost 50% of diabetic patients die within 3 years after beginning hemodialysis treatment (1) . Although much progress has been made over the past 10 years in free islet transplantation (Tx) with the Edmonton protocol, this procedure has required pooling of islets from multiple deceased donor pancreas grafts to achieve insulin independence (2) . The insufficient number of islets obtained from partial pancreatectomy further limits the effectiveness of living-related islet Tx. Therefore, it is necessary to develop innovative strategies specifically designed to maximize the safety and effectiveness of living-related islet Tx.
We have previously demonstrated the importance of vascularization of allograft tissue for the induction of tolerance in both a thymic Tx model (3) (4) (5) and an islet Tx model (6, 7) in miniature swine by using our unique techniques in developing thymo-kidneys and islet-kidneys (IK). The Tx of IKs involves donor islet vascularization as a part of the donor kidney before allogeneic Tx, and this technique allows the successful induction of tolerance of both the kidney and the islets from a single donor in a swine model (6, 7) . The innate tolerogenic qualities of the kidney provide immunoprotection for the engrafted, vascularized islets, when they are transplanted as part of the composite IK. This "Trojan horse" approach in transplanting a composite IK graft is particularly important for islet survival. We have previously demonstrated that simultaneously transplanting the kidney and the allogeneic free islets did not prolong islet survival when they were not transplanted as a vascularized component of the IK.
Although miniature swine have proved to be an excellent large animal preclinical model with respect to many parameters of Tx (8) , studies in nonhuman primate models are important for confirming clinical applicability. We have recently reported that baboon recipients of IKs possessed stable renal and islet function for >200 days with chronic immunosuppression (9) . Data from our baboon IK transplants demonstrated that (i) the procedures for IK preparation and composite IK Tx are feasible in nonhuman primates and that (ii) an immunosuppressive regimen that is used in clinical renal Tx, consisting of tacrolimus and mycophenolate mofetil, successfully maintains the vascularized islets of IKs, which does not occur in allogeneic free islet Tx. In the present study, we aimed to develop a clinically applicable tolerance-inducing regimen, specifically designed for living-related Tx procedures for patients with ESRD by combining IKs with hematopoietic stem cell (HSC) Tx in rhesus macaques.
Materials and Methods

Animals
Seven mother-son pairs of rhesus macaques (Macaca mulatta) were purchased from Covance (Homestead, FL). All animals were vaccinated and free of Mycobacterium tuberculosis, herpes simian B virus, simian immunodeficiency virus, simian T lymphotropic virus type 1, measles virus, and simian type D retrovirus serotypes 1, 2, 3, and 5.
Mobilization of donor HSC
Granulocyte-colony stimulating factor (GCSF) (100 lg/kg) and AMD3465 (1 mg/kg), an inhibitor of C-X-C chemokine receptor type 4 (CXCR-4), were administered intravenously. Leukapheresis of the donors was then performed, and the recipients were conditioned with the irradiation, T cell depletion, and cyclosporine A (CyA) (ITC) regimen (see later) as previously described (10) .
Leukapheresis
Leukapheresis was performed in a similar manner as previously reported (10) . Donor macaques were leukapheresed by using a Cobe Spectra Auto PBMC kit (Gambro, Denver, CO) and Auto PBMC kit (Gambro) for 4-6 h under general anesthesia. Macaques were sedated with 10 mg/kg ketamine, and general anesthesia was maintained with isoflurane. During the leukapheresis, two intravenous catheters were used as a central access line and a peripheral return line. The blood circulating through the leukapheresis machine was anticoagulated at a 10:1 ratio of blood to citratephosphate-dextrose solution with adenine. White blood cell count, hematocrit, hemoglobin concentration, platelet count, and serum chemistries of donor macaques were monitored. After leukapheresis, saline was used to rinse the collection tubing. The resulting rinse-back product was centrifuged at 900 9 g for 12 min, and the packed red blood cells were isolated and transfused into the donor.
Immunosuppressive ITC regimen
The sons of the rhesus macaque mothers received eight doses of antimonkey CD3 immunotoxin (11) (NHP Reagent Resource Center, Boston, MA) at 25 lg/kg twice daily starting on day -4, 100 cGy total body irradiation (TBI) on day -2, and 45 days of CyA starting 1 day before the HSC Tx from their mothers (day 0). We refer to this conditioning protocol as the ITC conditioning regimen.
Surgical procedures
Living-donor partial pancreatectomy for isolation of islets for IK preparation: Partial pancreatectomy was performed as previously reported (9) .
Islet preparation: Pancreata were infused with Liberase HI and subjected to digestion. The digested tissue was filtered through a mesh screen, applied to a discontinuous gradient, and centrifuged for purification. Islets were then collected, washed, and transplanted as previously reported (9) .
Preparation of IK:
The IK preparation was performed in the same manner as previously reported in a baboon model (Yamada IK procedure) (9) .
Induction of diabetic hyperglycemia using streptozotocin:
Recipient animals were given a single bolus of intravenous streptozotocin (STZ) at 80-85 mg/kg, a dose that is a substantially higher than the dose used for cynomolgus monkeys (12) .
Transplantation of IKs from the HSC Tx donors (mothers) to sons across a haplo-mismatched barrier: Composite IKs were transplanted in a manner similar to living-related pediatric renal Tx (13) . Details of the procedure are given in our previous reports (9) . The IKs were transplanted on day 208 (animal S0610) or days 20-22 after HSC Tx (animals S8710, S1010, and S9110). The native kidneys were removed at the time of the IK Tx.
Intravenous glucose tolerance test
The intravenous glucose tolerance test was performed by administering an intravenous infusion of 0.5 g/kg glucose, and serial blood glucose (BG) levels were subsequently measured.
Immunologic assays
Chimerism: Peripheral blood macrochimerism was measured with a Becton Dickinson FACScan microfluorometer (Sunnyvale, CA) as previously described (14) twice a week during the first month until the loss of chimerism.
Mixed lymphocyte reaction assays: Cellular anti-donor responses
were assessed by mixed lymphocyte reaction (MLR) assays performed as previously reported (15) .
Anti-donor antibody testing: Development of anti-donor IgM and IgG antibodies after the IK Tx was assessed by immunofluorescence staining of biopsied/excised IK samples using frozen sections. After HCT Tx, sera from animal S0409 were tested by flow cytometric analysis (FACS) to determine whether the animal developed anti-donor IgM or IgG before kidney Tx.
Histologic examination
Sections were examined by a renal pathologist after both hematoxylin and eosin (H&E) and immunohistochemistry staining by using rabbit anti-human CD3 (ThermoFisher, Rockford, IL), guinea pig anti-insulin (Dako, Carpinteria, CA) primary antibodies, and the standard avidinbiotin-peroxidase complex technique (9) .
Results
Transient chimerism, not long-term chimerism, was observed after HSC Tx with the ITC regimen in a mother-to-son combination T cell depletion by the ITC regimen: Seven rhesus macaque recipients (sons) received the ITC regimen. This regimen reduced the number of CD3 + T cell count to <50 cells/lL by the time of the HSC Tx. However, the number of T cells subsequently increased, and the number of CD3 + T cells reached >300 cells/lL by day 14 after the HSC Tx ( Figure 1A ). The number of T cells returned to >500 cells/lL by the completion of immunosuppression and to >1500 cells/lL by 3 months after the induction treatment. Of the seven HSC Tx recipients, two animals were used to optimize the HSC Tx conditions for in vitro testing (animals S0209 and S0609), one received a donor kidney graft (animal S0409), one received a donor kidney followed by an IK from the HSC donor (animal S0610), and three received IKs from HSC donors (animals S8710, S1010, and S9110 -see details in the following sections).
HSC Tx at day 0: Recipients treated with the ITC regimen received leukapheresed products intravenously from their mothers. These products contained a total of 1.5-6.5 9 10 9 mononuclear cells and 1.1-5.1 9 10 6 CD34 + T cells in a final volume of 30-85 mL (Table 1) .
Macrochimerism in peripheral blood: After HSC Tx, macrochimerism in the peripheral blood was assessed by using an H38-specific monoclonal antibody in three of the seven recipients (animals S0209, S0610, and S1010) ( Figure 1B ). Because this study required a mother-to-son HSC Tx, availability of the H38 antigen in the colony was limited and thus could not be used to assess macrochimerism in all recipients.
A small percentage of circulating H38 + donor cells in the total leukocytes of the peripheral blood was detected on day 1 (5% in animal S0209, 5% in animal S0610, and 8% in animal S1010), day 2 (2% in animal S0209, 1% in animal S0610, and 2% in animal S1010), and day 3 (1% in animal S0209, 1% in animal S0610, and 1% in animal S1010). However, these donor cell populations subsequently decreased to <1% and were below the level of detection (<0.5%) at the time of a primary kidney Tx (animal S0610) or an IK Tx (animal S1010) ( Figure 1B ).
Acceptance of haploidentical kidneys with the ITC regimen
We tested whether a one-haploidentical kidney allograft was accepted with the ITC regimen. Animal S0409 received an HSC Tx from the mother as well as the ITC regimen, and the donor kidney was transplanted 105 days after the HSC Tx without further immunosuppression. Although the animal possessed a small number of circulating donor cells during the induction period as described here earlier, neither microchimerism nor macrochimerism was detected in bone marrow samples at days 55 and 100. The numbers of both T and B cells returned to pre-HSC Tx levels at the time of the kidney Tx. The number of CD20 + cells recovered to 5000 cells/ lL, and the number of while no anti-donor antibodies were detected by FACS analysis (Figure 2A and B).
After the donor-matched kidney Tx, creatinine (Cr) levels were stable at <1 mg/dL during the first 4 weeks. The animal experienced transient elevated Cr periods twice due to either dehydration or a ureteral stent occlusion by debris, and these issues were resolved by hydration and/ or replacement of a ureteral stent ( Figure 3 ). Kidney biopsies at days 41 and 75 after kidney Tx showed infiltrate and chronic tubular changes, but there was no evidence of endothelialitis ( Figure 4B-a and -b) . Although antidonor responses before kidney Tx demonstrated only slight hyporesponsiveness against the donor, antidonor responses decreased over time while anti-third party responses were maintained after kidney Tx ( Figure 4A ). Immunofluoresence specimens showed IgM deposits as well as C3 and C4d, but no IgG deposits were observed ( Figure 4B -c-f), indicating a class switch from IgM to IgG did not occur.
A second animal, S0610, had a clinical course similar to that of S0409. As described earlier, this animal showed low levels of transient macrochimerism (5% at day 1 and 1% at day 2), but no detectable chimerism was noted at the time of the kidney Tx (day 20). This animal had stable renal function after a one-haploidentical kidney Tx with the ITC regimen and received an IK from the same donor on day 208 (details are given in the next section). Days post HSC Tx Figure 3 : Serum creatinine levels (mg/dL) after kidney transplantation in animal S0409, the animal that received an allogeneic kidney from the HSC donor on day 105 after HSC Tx without immunosuppression. Two transient rises in serum creatinine levels were caused by either dehydration or ureteral stent occlusion by debris and were resolved by hydration and/or replacement of the ureteral stent. HSC, hematopoietic stem cell; Tx, transplantation.
S0409 IgM S0409 IgG
Successful induction of tolerance of both islet and kidney as a composite, vascularized IK Successful isolation of islets for IK preparation in rhesus macaques: Five IKs were prepared in five donors (mothers) in the same manner as described previously in the baboon model (9) . Islets from a 70% distal pancreatectomy were successfully isolated in each case, and yields of islets were between 2.4 9 10 4 islet equivalents (IE) and 4.5 9 10 4 ( Table 1) . One IK was used for histological analysis (IK of animal S0309, who donated a kidney graft only to animal S0409), and four were transplanted into recipients. No surgical complications occurred during or after the IK preparation. The BG levels of the donors were in the normal range after IK preparation, and they remained normal even after removal of the IK grafts. This indicates that 70% partial pancreatectomy for IK preparation is safe for donors in the rhesus macaque model, which was expected based on our previous experience with IK preparation in the swine (6,7) and baboon models (9) ( Figure 5 ).
Acceptance of an IK graft without immunosuppression in a recipient that had previously accepted a kidney from the same donor: To address if (i) the ITC regimen-induced tolerance of the kidney and whether (ii) tolerance of the kidney allowed the donor islets to function without additional treatment, animal S0610, which had accepted a one-haploidentical kidney from the mother (described earlier), received an IK from the same donor on day 208 after HSCT Tx without immunosuppression. The recipient monkey received STZ at 80 mg/kg (bolus intravenous injection) at 7 days before the IK Tx. STZ treatment successfully induced insulin-dependent diabetes mellitus (DM), for which the animal required >20 U of insulin to maintain BG levels at <300 mg/dL ( Figure 6) . The IE:recipient's body weight ratio was calculated based on numbers at the time of the IK preparation. After the IK Tx, which contained >8000 IE/kg, BG levels immediately decreased and no insulin treatment was required during the first 2 days after the IK Tx ( Figure 6 ). Although a minimal amount of insulin treatment (0.5-3 U) was required occasionally thereafter, the animal remained active during the 450 days post ITC regimen as well as during the 242 days post IK Tx. On day 242 after the IK Tx, we removed the IK graft to confirm that maintenance of BG levels was solely promoted by the transplanted islets of the IK graft. BG levels increased to >600 mg/dL within 12 h after removal of the IK, indicating that no residual functioning islets remained in the host pancreas. We euthanized this animal 2 days after the removal of the life-supporting IK graft. Histology of the excised IK graft on day 242 showed viable islets under the kidney capsule of the IK, and no rejection was observed in the kidney sections of the IK (Figure 7A and B) . Immunofluorescence staining of the IK was negative for IgM (c), IgG (d), C3 (e), and C4d (f) in the IK graft.
Transplantation of an IK at day 20 after HSC Tx with the ITC regimen: We next assessed whether IK grafts were accepted with the ITC regimen in a similar manner to that of the kidney alone. Three recipients (animals S8710, S1010, and S9110) received HSC Tx (day 0) from their mothers, as well as the ITC regimen. IK grafts were then transplanted on days 20-22 ( Figure 8) . DM was induced with STZ at 80-85 mg/ kg at 5-7 days before the IK Tx. All recipients successfully developed DM, and BG levels reached >600 mg/dL. Similarly to the previous animal (S0610), >20 U of insulin was required to maintain BG levels <300 mg/dL ( Figure 9A-C) .
All three animals accepted the IK grafts; however, insulin requirements among these animals varied after IK Tx. In addition, the insulin requirements appeared to correlate with the number of islets in the IK graft ( Figure 9A-C) . Animal 8710 received HSC Tx on day 0 with the ITC regimen, and the IK (9000 IE/kg) was transplanted at day 20.
Blood glucose levels after IK preparation Cr levels were <1.2 mg/dL and BG levels were <120 mg/ dL after the IK Tx ( Figure 9A ). No insulin treatment was required following the IK Tx, but the animal developed bowel intussusception and was euthanized on day 69.
Histologic examination of the excised IK confirmed the presence of viable insulin-producing islets under the kidney capsule without any evidence of rejection (Figure 10A-a) . Recipients received twice-daily doses of anti-monkey CD3 immunotoxin (CD3 IT) (25 lg/kg) on days -4, -3, -2, and -1 before HSC Tx. Then, 100 cGy of TBI was given on day -2. Cyclosporine was administered from day 0 to day 45 following HSC Tx (target blood nadir levels 400-600 ng/mL). CyA, cyclosporine A; TBI, total body irradiation; HSC, hematopoietic stem cell; IK, islet-kidney; Tx, transplantation.
However, both animals S1010 and S9110, which received IKs containing 6880 and 5000 IE/kg, respectively, required insulin treatments during the 45-day period of CyA ( Figure 9B and C). Animal S1010 received an IK containing 6880 IE/kg 20 days after the HSC Tx. The animal received 3-5 U of insulin/day during the high-dose CyA period, but after the cessation of CyA, only ≤2 U/day were required to maintain BG levels at <150 mg/dL ( Figure 9B ). To address whether additional islets from the same donor, without immunosuppression, decreased the requirement for exogenous insulin, we transplanted islets (2000 IE/kg), which were isolated from the residual pancreas of the donor, through the host's inferior mesenteric vein on day 112 after the IK Tx. Insulin requirement was markedly decreased after this additional small-dose islet infusion ( Figure 9B ). However, BG levels slowly increased thereafter and occasionally exceeded 150 mg/dL. Cr levels were stable throughout the experimental period until the IK graft was removed on day 342. After removal of the IK, BG levels immediately increased, indicating islets injected in the liver had lost function. Histology of the excised IK showed numerous insulin-stained islets within the renal capsule without evidence of rejection ( Figure 10A-b) .
The third animal, S9110, received an IK with 5000 IE/kg 20 days after the HSC Tx. This animal required insulin treatments at relatively high doses (5-8 U during the 45 days of high-dose CyA). However, similarly to animal S1010, <2 U of insulin were required to maintain BG levels <150 mg/dL after cessation of CyA ( Figure 9C ). Cr levels were stable throughout the IK period except around day 140, when a stent replacement was performed.
Immunofluorescence staining of the excised IK was negative for both IgM ( Figure 10B-a) and IgG ( Figure 10B-b) .
MLR data from these three recipients are shown in Figure 11 . MLR data at 7 weeks after IK transplant showed either similar levels or slightly decreased antidonor proliferative responses compared with that against third party allogeneic stimulators.
Discussion
Despite improvements in BG management, patients with type 1 diabetes mellitus (T1D) continue to have a significant risk of developing ESRD. It has been estimated that 20-50% of patients with T1D will develop ESRD, eventually requiring hemodialysis or kidney Tx (16) . Simultaneous kidney-pancreas Tx is an excellent treatment strategy for T1D patients with ESRD that can restore euglycemia and resolve uremia. However, there are Blood sugar levels (mg/dL) and requirement of rapid insulin (U) before and after IK Tx in animals S8710 (A), S1010 (B), and S9110 (C). These animals were transplanted with an IK on days 20, 22, and 22 post HSC Tx, respectively. Animal S8710 was killed on day 69 due to gastrointestinal complications. Animal S1010 received an additional 2000 IE/kg from the original islet donor, which was administered in the mesenteric vein on day 112. Anmals S1010 and S 9110 had their IKs removed on days 342 and 242 after HSC Tx, respectively. In both cases, a rapid rise in BG was observed, confirming that stable BG levels were solely maintained by the IK grafts. BG, blood glucose; HSC, hematopoietic stem cell; IK, islet-kidney; Tx, transplantation.
several drawbacks to this therapeutic option from both the surgical and immunological perspectives. From the surgical standpoint, pancreas Tx is associated with relatively high perioperative morbidity. Early postoperative complications such as graft thrombosis, hemorrhage, pancreatitis, and enteric intestinal leak occur in 10-15% of the cases, significantly increasing the risk of graft loss (17) . From the immunological perspective, lifelong immunosuppressive medication entails risks such as increased susceptibility to infection and an increased risk of malignancy (18, 19) . Most patients with T1D who will progress to ESRD will do so at a young age and unfortunately will have to endure the risks associated with immunosuppressive medications for the rest of their lives. In addition to these considerations, rejection of the pancreas can negatively influence both kidney allograft and overall patient survival.
In our clinically relevant baboon model, we previously demonstrated the feasibility of IK Tx, showing that this technique can simultaneously cure DM and restore euglycemia in the setting of a chronic immunosuppressive regimen currently used clinically for kidney Tx (9) . The IK tolerance strategy reported in this study serves as a precursor for clinical trials, as it has several advantages with respect to the therapeutic options available to patients with T1D and ESRD. The first advantage is that our IK technique allows achievement of tolerance of both kidneys and islets simultaneously, and to our knowledge, this is the first example of achieving such tolerance in a preclinical primate model. The second advantage is that our IK method offers a considerably simplified surgical procedure for the recipient and significantly reduces the numerous complications associated with simultaneous kidney-pancreas Tx. The third advantage is that our ITC regimen can achieve immunological tolerance without the need for stable or long-term mixed chimerism, which has posed the risk of graft-versus-host disease in other clinical models in which longer persistence of peripheral bone marrow chimerism is required.
The results in this study also suggest that it is necessary to optimize the preclinical model before this technique can be applied in clinical practice. Although we have been able to achieve insulin independence with our IK procedure in swine and baboon preclinical models by using islets isolated from a 70% distal pancreatectomy (7, 9) , rhesus monkey recipients required occasional insulin treatments, with the exception of one monkey that possessed the highest IE/kg ratio in the study and subsequently did not require insulin therapy after allogeneic composite IK Tx. Although this may be rhesus monkey specific, we are currently developing strategies to further preserve the function of islets, which include (i) reduction of CyA dosing, as this drug has a diabetogenic effect (20) ; (ii) delayed IK Tx, which will minimize CyA exposure; (iii) use of nondiabetogenic medications after allogeneic IK Tx; (iv) improved islet isolation techniques for nonhuman primates (we currently collaborate with a core laboratory at the Massachusetts General Hospital [MGH] for islet isolation); and (v) modulation of the transplantinduced proinflammatory state by a 1 -antitrypsin administration, a drug that modulates inflammation and therefore could play an islet-protecting role (21) at the time of IK preparation as well as IK Tx.
The ITC regimen in rhesus monkeys facilitated acceptance of haploidentical kidneys or IKs despite only transient macrochimerism and presence of in vitro antidonor MLR responses. In our previous studies using similar mild conditioning protocols for hematopoietic cell Tx in swine, we found that in vitro MLR responses did not correlate well with donor kidney graft acceptance (22, 23) . Data generated using this same ITC conditioning protocol in swine suggest that exposure to donor cells using this novel conditioning protocol results in robust, stable immune modulation of donor-specific antibody responses together with transient immunomodulation of T cell responses (24 and unpublished data). The mechanism of immunomodulation mediated by allogeneic cells in this model is unrelated to HSC engraftment. When donor antigen is provided during the early period of immunomodulation in the form of a kidney allograft, T cell tolerance is also maintained, resulting in stable renal allograft tolerance. We are currently exploring the mechanism of allograft tolerance in this model.
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Anti third-party Anti Donor : MLR data from animals S0610, S8710, S9110, and S1010 before, 7 weeks after, and 15 weeks after IK Txs. These animals were relatively hyporesponsive against donors, but donor-specific unresponsiveness was not induced. MLR, mixed lymphocyte reaction; Tx, transplantation.
One critique that may arise in response to our protocol is the question of risk associated with IK preparation for the donor. To date, >160 living pancreas Txs have been reported in the literature, and more than three-quarters of these procedures have been performed at a single institution, the University of Minnesota (25) . Experienced surgical teams perform the surgical procurement safely, and no fatalities have been reported. The risk of developing diabetes after pancreas donation has been reported to be 3% in the past; however, after more stringent criteria were adopted for donor selection, no significant metabolic perturbations were observed after the operation. Despite the high success rate of this procedure, living-donor pancreas Tx has been performed very infrequently in recent years. Although we must first determine the optimal conditions for successful full reversion to normoglycemia in T1D recipients with IK prepared from 70% pancreatectomy as described earlier, it is clearly safe for the potential donors to undergo this pancreatic mass excision. With combined strategies to improve islet quality and inhibit innate immune responses, we will determine the minimal pancreatectomy required for a safe and successful IK preparation. Further, we can reduce the surgical insult in the recipient by preparing the IK laparoscopically, which is an approach that has already been applied to living-donor pancreas procurement (26) .
Our IK tolerance strategy offers a novel therapeutic approach for patients with ESRD and T1D and is specifically designed for living-related Tx. The application of living-donor partial pancreas Tx has remained anecdotal since its first report, and the use of a living-donor partial pancreas procurement for islet preparation and subsequent free islet injection is limited by the number of isolated islets, which is insufficient to reverse T1D successfully. Much of the progress made in free islet Tx over the past four decades has required pooling of islets from multiple deceased donor pancreas grafts to achieve insulin independence (2, 27) , and there have been no successful cases of allogeneic islet Tx using islets from a 70% distal pancreas in preclinical models without the IK strategy (7, 9) . The composite IK is an innovative strategy that allows us to both minimize the loss of islets associated with the enhanced innate immune response after allogeneic islet Tx and eliminate the surgical risks of pancreas Tx in the recipient. Moreover, using a living donor eliminates the need to wait for a deceased donor to become available and allows the opportunity for a paired donation. In addition to eliminating the risks of lifelong immunosuppression, immunologic tolerance is an attractive option for patients who are sensitized to HLA antigens. We believe that our IK tolerance strategy offers many significant advantages to the patient with ESRD and T1D. Although further optimization is required, the safety and effectiveness of our IK preparation and procurement procedures markedly reduce the risks to the donor of IK Tx.
